Sugi Predict

Sugi Predict / Compounds / SCHEMBL15740329

SCHEMBL15740329

SCHEMBL15740329

Nc1nc(O)c(CC(=O)O)s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.56
▸ ALDH1A1 P00352 3/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ MAPT P10636 1/20 0.45
▸ GABRA5 P31644 2/20 0.43
▸ GABRB2 P47870 2/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ ADAMTS5 Q9UNA0 1/20 0.42
▸ CDK2 P24941 2/20 0.41
▸ CDK1 P06493 1/20 0.41
▸ CCNB1 P14635 1/20 0.41
▸ PTGDR2 Q9Y5Y4 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ COPS5 Q92905 3/20 0.36
▸ TRPM8 Q7Z2W7 1/20 0.35
▸ GABRA1 P14867 1/20 0.34
▸ GABRR1 P24046 1/20 0.34
▸ SLC6A12 P48065 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8434293 0.81 MAPT (0.49) CYP1A2ALDH1A1MEN1KMT2AMAPT
SCHEMBL5026007 0.78 CYP1A2 (0.54) CYP1A2ALDH1A1MEN1KMT2AMAPT
SCHEMBL27769969 0.77 CYP1A2 (0.53) CYP1A2ALDH1A1MEN1KMT2AMAPT
Bromide SCHEMBL11363387 0.77 CYP1A2 (0.53) CYP1A2ALDH1A1MEN1KMT2AMAPT
SCHEMBL25834239 0.76 PTGDR2 (0.51) CYP1A2ALDH1A1MEN1KMT2AMAPT
SCHEMBL27734024 0.76 CYP1A2 (0.51) CYP1A2ALDH1A1MEN1KMT2AMAPT
SCHEMBL27719752 0.76 CYP1A2 (0.51) CYP1A2ALDH1A1MEN1KMT2AGABRA5
SCHEMBL27748632 0.73 CYP1A2 (0.49) CYP1A2ALDH1A1MEN1KMT2AGABRA5
SCHEMBL11872214 0.72 CYP1A2 (1.00) CYP1A2ALDH1A1MEN1KMT2AMAPT
SCHEMBL28768528 0.72 CYP1A2 (0.48) CYP1A2ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-07-20 — — US disclosed
US-11395820-B2 Small molecules against cereblon to enhance effector t cell function H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2022-07-26 — — US disclosed
US-20210177825-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2021-06-17 — — US disclosed
WO-2017161119-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) 2017-09-21 — — WO disclosed
WO-2014081856-A2 LIGANDS THAT TARGET HCV-E2 BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM AZZAZY HASSAN (EG) 2014-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11395820-B2 Small molecules against cereblon to enhance effector t cell function CD4, GZMB, CRBN CYP1A2 4739/4885ALDH1A1 4134/4885MEN1 1005/4885
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION CD4, CRBN, GZMB CYP1A2 4310/4885ALDH1A1 4309/4885MEN1 738/4885
US-20210177825-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION CD4, GZMB, CRBN CYP1A2 4739/4885ALDH1A1 4134/4885MEN1 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.